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ABSTRACT 
Peptic ulcer embraces both gastric and duodenal ulcers and has been a major threat to the world’s population over the past 
two centuries, with a high morbidity and substantial mortality. Discovery of gastric mucosa infection with Helicobacter 
pylori (H. pylori) and its association with chronic antral gastritis and peptic ulcer revolutionized the treatment of ulcer 
illness. H. pylori are causally related to a majority of cases of both duodenal and gastric ulcer, in the west and developing 
countries. Despite extensive scientific advancements, this disease remains an important clinical setback, largely because of 
H. pylori infection and widespread use of non-steroidal anti-inflammatory drugs (NSAIDs). Management of peptic ulcer 
disease generally involves the practice of H2 receptor antagonists, use of proton pump inhibitors, antacids and different H. 
pylori eradication regimens. This review article outlines the epidemiology, clinical manifestations, diagnosis and treatment 
strategies of peptic ulcer disease.    
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INTRODUCTION 
Peptic ulcer disease is a group of disorders characterized by 
the presence of ulcers in any portion of gastrointestinal tract 
(GIT) exposed to acid in sufficient concentration and 
duration. Although these ulcerations most commonly occur 
in the stomach (gastric ulcer), or small intestine (duodenal 
ulcer), this disease also includes Barrett ulcer of the 
esophagus (Barrett’s esophagus or Barrett’s metaplasia) and 
other upper GI ulcers. 
[1] An ulcer is a crater like lesion in a 
membrane; ulcers that develop in areas of the GIT exposed to 
acidic gastric juice are called peptic ulcers. 
[2] Word ‘peptic’ 
derives from the Greek term ‘peptikos,’ meaning related to 
digestion. 
[3] Peptic ulcer is due to exposure of stomach and 
duodenum to pepsin and gastric acid. Imbalance occurs 
between aggressive factors like acid, pepsin, H. pylori and 
defensive factors such as gastric mucus, bicarbonate ions, 
and prostaglandins along with innate resistance of mucosal 
cells. 
[4] Gastroduodenal mucosa utilizes several defense 
mechanisms against the aggressive factors such as 
hydrochloric acid and pepsin. 
[5] 
Danish physiologist Schierbeck in 1892 reported that food 
ingestion caused an increase in canine gastric CO2. However,  
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few years later, Pavlov investigated about the protective role 
of gastric alkaline mucus.  
It is well established that gastric and duodenal epithelial cells 
in mammals actively secrete bicarbonate into the lumen. 
[6-7] 
This secretion interacting with the surface mucus gel layer 
comprises first line of mucosal defense. 
[5] Proximal duodenal 
mucosal bicarbonate secretion capacity in man is about five 
times the gastric bicarbonate secretion. 
[8] Mucus is secreted 
by mucus secreting cells that are available abundantly in the 
neck region of gastric glands. Mucin forms a protective layer 
on the gastric epithelium. It retains bicarbonate and has 
alkaline pH. Thus, it protects the stomach from acid peptic 
digestion, as it buffers hydrochloric acid. Mucus secretion is 
also stimulated by increased blood flow to the stomach. 
[9] 
Activation of prostaglandin receptors also inhibits gastric 
acid secretion. Mucosal prostaglandins are known to afford 
cytoprotection by various mechanisms. 
[10]  
Natural aggressors secreted into the gastric lumen are acid 
and pepsin. Various studies reveal that the gastroduodenal 
mucosal barrier is damaged by pepsin under conditions in 
which it is resistant to acid alone. Pepsin has mucolytic 
activity and progressively digests the adherent mucus layer at 
its luminal surface. 
[11] Studies by Taylor and Roberts have 
identified, on the basis of charge differences, seven pepsins –
1, 2, 3, 3a, 4, 5, and 6 in human gastric juice and acidified 
extracts of gastric mucosa. 
[12-13] The most common cause of 
ulcer is H. pylori, a bacterium that colonizes the stomach of 
nearly half the world’s population. Infection caused by H. Pahwa et al. / Clinical Manifestations, Causes and Management Strategies ………………. 
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pylori is causally linked with many GI diseases, including 
upto 75% of peptic ulcers. 
[3] Moreover, NSAIDs along with 
H. pylori combine the caustic effects of gastric acid and 
pepsin, which disrupts the normal defense mechanism of the 
GI mucosa. 
[14] Various protective and aggressive factors are 
summarized below: 
[15]   
Protective factors:  Aggressive factors: 
¾  Bicarbonate    Acid  
¾  Mucus    Pepsin 
¾  Mucosal blood flow    Helicobacter pylori  
¾  Prostaglandins    NSAIDs 
 
HISTORY AND PREVALENCE 
Indigestion and heartburn have been described for thousands 
of years, but it was only in the 16
th century that the disease 
peptic ulcer was established by autopsy. One of the first 
autopsies - proven pyloric peptic ulcers was studied in 1586 
by Donatus of Mantua. Bauhin, in 1679, concluded that 
inflammation of the stomach led to a gastric ulcer which then 
ruptured. The first known gastric hemorrhage was reported in 
1704. 
[16] First classification of stomach diseases came in 
1793 from Matthew Baillie, with clear descriptions of acute 
inflammation (arsenic), trichobezoar, ulcer, perforation, 
pyloric stenosis, scirrhous and ulcerated cancer. In 1817, 
patients with perforated gastric ulcer were reported in Dublin 
by Crampton and patients with perforated duodenal ulcer 
were reported in London by Travers, who also noted 
bleeding, stenosing and penetrating gastric ulcers. 
[17-19] The 
first epidemiological study on peptic ulcer in North India was 
conducted in 1963. 
[20]  
Approximately 5,00,000 new cases and 4 million recurrences 
of peptic ulcer are reported each year, contributing to the 
approximately 10% of Americans developing peptic ulcer 
disease during their lifetime. 
[21-22] Complications of peptic 
ulcer disease, including perforation, bleeding, and 
obstruction, occur in up to 20 % of cases; overall, gastric 
outlet obstruction may affect 5% - 12% of peptic ulcer 
patients. 
[23] Johnson et al noted that peptic ulcer disease was 
the origin of obstruction in 62 % of patients from 1962 to 
1975, and in 45 % of patients from 1975 to 1985. 
[24] Gibson 
et al investigated that only 33 % of patients in their series 
with peptic ulcer disease and outlet obstruction were H. 
pylori positive. 
[25]  The annual incidence of gastric ulcers 
varies from approximately 1 case per 1000 population in 
Japan to 1.5 cases per 1000 population in Norway to 2.7 
cases per 1000 population in Scotland. 
[26] Commonly, the 
ratio of duodenal ulcer to gastric ulcer varies with place and 
time. In most countries, duodenal ulcers are about three times 
more common than gastric ulcers, but gastric ulcers are more 
common in some locations such as Japan, Sri Lanka, the 
Andes and some islands off northern Norway. 
[27]   
REGULATION OF GASTRIC ACID SECRETION 
Stomach secretes about 2.5 liters of gastric juice daily. The 
primary exocrine secretions are pepsinogens, from the chief 
or  peptic cells, and hydrochloric acid and intrinsic factor 
from the parietal or oxyntic cells. 
[28] Men secrete more acid 
than women. This can be explained partially by differences in 
body size. 
[29] Gastric acid secretion is regulated by intricate 
central and peripheral mechanisms. Parietal cells have 
receptors for several stimulants of acid secretion and these 
cells possess a specific Hydrogen Potassium-ATPase enzyme 
(proton pump), which is responsible for the exchange of  H
+ 
for K
+ ions across the apical surface of the parietal cells. The 
final process of acid transport per se rests with this enzyme. 
Three distinct but interdependent pathways deliver chemical 
messengers that stimulate acid secretion as shown in Fig. 1 
and are summarized in the following text. 
•  The neurocrine pathway, that acts through the 
transmitters such as acetylcholine. 
•  The paracrine pathway delivers tissue factors, such 
as histamine from enterochromaffin like cells.  
•  The endocrine pathway delivers hormones such as 
gastrin from antral G cells. 
[30] 
The receptors on the surface of parietal cell include H2 
receptors responding to histamine released from specialized 
mast cells, receptors that are sensitive to the muscarinic 
effects of acetylcholine released from the vagus nerve and 
probably receptors responsive to endogenous circulating 
gastrin. A stimulated receptor modifies the activity of other 
receptors and at the same time releases an intracellular 
second messenger. Calcium ions and cyclic AMP are the 
principal second messengers, and these in turn activate the 
gastric proton pump situated near the luminal apex of the 
parietal cell. 
[31] 
More data are also available on the role of GI hormones in 
the regulation of aggressive factors, especially gastric acid. In 
fact, the antral hormone gastrin was detected by its property 
to stimulate gastric acid secretion. 
[32] In 1971, McGuigan 
and Trudeau observed that patients with duodenal ulcer had 
an exaggerated gastrin release in response to meals and 
suggested that the trophic effect of gastrin might be 
responsible for the increase in parietal cell mass 
characteristic of duodenal ulcer disease. 
[33] In the late 1980s, 
several investigators also examined meal-stimulated gastrin 
release in relation to H. pylori infection. 
[34] 
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Fig. 1: Mechanism involved in regulation of gastric acid secretion by the 
parietal cells 
R= Receptors, EP3= PG receptor for PGE2, M1= Muscarinic receptor, ECL= 
Enterochromaffin like cells, Ach = Acetylcholine, H2 = Histamine 
 
TYPES OF PEPTIC ULCER 
Ulceration of the gastrointestinal mucosa is caused by 
disruption of normal balance of the corrosive effect of gastric 
juice and the protective effect of mucus on gastric epithelial 
cells. On the basis of location, peptic ulcers are categorized 
as follows - Gastric ulcer: means occurrence of ulcer in 
stomach. These ulcers occur more generally in the older age 
group.  
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Duodenal ulcer:  Occurrence of ulcer in the duodenum is 
referred as duodenal ulcer. These ulcers are more common 
than gastric ulcers. They occur commonly in younger 
individuals and are evenly distributed among various socio-
economic groups. Duodenal ulcer patients have higher than 
normal levels of acid secretion rates. 
[35, 29, 30] Depending on 
severity, peptic ulcers are also classified as: Acute peptic 
ulcers:  These ulcers involve tissues to the depth of the 
submucosa. They may arise in the form of single or multiple 
lesions.  They are found in many sites of stomach and in the 
first few centimeters of duodenum. Chronic peptic ulcers: 
These ulcers penetrate through the epithelial and muscle 
layers of stomach wall and may include the adjacent pancreas 
or liver. In majority of cases, they occur singly in the pyloric 
antrum of the stomach and in duodenum. 
[36]      
H. PYLORI INFECTION  
H. pylori infection plays a crucial role in the pathogenesis of 
peptic ulcer disease. More than 95 % of patients suffering 
from the duodenal ulcers and about 70 % - 80 % of patients 
with gastric ulcers are H. pylori positive. 
[37] H. pylori is a 
gram-negative, motile, microaerophilic, curved bacillus that 
is found in the mucus layer overlying the gastric epithelium. 
[38] In 1981, Marshall and Warren conducted a prospective 
study of 100 consecutive patients undergoing endoscopy to 
correlate gastric mucosal biopsy findings with clinical and 
endoscopy data. In this investigation, they isolated 
microaerophilic, catalase-positive bacterium. 
[39]  H. pylori 
infection has been recognized as the primary cause of chronic 
gastritis and peptic ulcer disease. 
[38] In 1994, United States 
(U.S.) National Institutes of Health Consensus Development 
Panel concluded that infection appears to play an important 
contributory role in the pathogenesis of peptic ulcers. 
[40] The 
role of H. pylori infection is well explained in peptic ulcer 
disease by O’connor. 
[41]  
Currently, 70 % of all gastric ulcers occurring in the U.S. can 
be attributed to H. Pylori infection. In addition to an increase 
in acid secretion, bacterial infection also predisposes patients 
to ulcer disease by disrupting mucosal integrity. 
[26] In 
developed countries, however, infection with H. pylori is 
uncommon before age 10 and increases to 10 % in 18 - 30 
years old, compared with 50 % in those older than 60. 
[42] In 
developing nations, 60 % - 70 % of children are infected with 
the bacteria by age 10, probably because of overcrowding 
and poor sanitation. 
[43] Chronic gastritis associated with H. 
pylori infection is often observed in children with primary 
duodenal ulcer. Colonization of the gastric mucosa by H. 
pylori is currently uncommon among children who live in 
industrialized countries, compared to those who live in 
developing countries, with prevalence upto the tenth year of 
life of 5 % - 10 % and up to 80 %, respectively. 
[44]
There are several strains of H. pylori along with two 
phenotypes of the bacterium. Both make a vacuolating 
cytotoxin Vac A. Type I also has a cytotoxin-associated gene 
(cag A) that may be necessary for transcription, function, or 
excretion of Vac A cytotoxin. This type I phenotype is 
associated with ulcer formation. Type II organisms lack cag 
A and do not produce as much of an inflammatory response. 
This bacterium also makes mucolytic enzymes, platelet 
activating factor, and lipopolysaccharide. Each of these can 
cause cellular injury. 
[45] Covacci et al have suggested that 
only bacteria expressing the cag A antigen are associated 
with ulcer disease. These findings explain the link between 
H. pylori cytotoxin expression and ulcer disease. 
[46-47] 
INDISCRIMINATE USE OF NSAIDs  
NSAID including aspirin use is the second most common 
etiologic factor for this disease and a major factor for peptic 
ulcer complications. 
[48] The function of long term NSAIDs 
use in various GI tract injuries has been well documented in 
commendable number of scientific publications. 
[49] Patients 
with rheumatoid arthritis and osteoarthritis who take NSAIDs 
have 15-20 % annual incidence of peptic ulcer. More than 
half of patients who present with peptic ulcer hemorrhage or 
perforation report the recurrent use of NSAIDs, including 
aspirin. 
[50] Aspirin has been indisputably correlated with this 
complication. 
[51] NSAIDs induce GI mucosal injury by direct 
toxic effects and reduce mucosal prostaglandins which play a 
critical role in defense mechanisms and repair processes. 
NSAIDs inhibit cyclooxygenase (COX), which is the rate-
limiting enzyme required for the conversion of arachidonic 
acid to prostaglandins. 
[52]  
H. pylori infection is a prevailing risk factor for peptic ulcer 
disease along with the widespread use of NSAIDs, grounds 
for evidence of ulcer development. Overall, the risk of 
developing an ulcer is at least 15 times higher in subjects 
infected with H. pylori than in those not infected with the 
bacterium. 
[53]  
OTHER CAUSES  
Numerous other factors causing this disease include smoking 
habits, alcohol consumption, coffee drinking and familial 
occurrences of peptic ulcers in patients with gastric or 
duodenal ulcer. 
[54] Epidemiologic studies suggest that 
smokers are about twice as likely to develop peptic ulcer 
disease as non-smokers. Smoking increase gastric acid 
secretion and duodenogastric reflux and decreases both 
gastroduodenal prostaglandin production and pancreatic 
duodenal bicarbonate production.
 [50] Lam et al have also 
documented that an unfavorable trend in duodenal ulcer 
healing exists for cigarette smokers as compared with non-
smokers who receive H2-blockers. 
[55]  
Conventionally, peptic ulcer disease has also been considered 
to be a stress-associated psychosomatic disease. Importance 
of emotional disturbances due to stress has long been shown 
to be a consideration in the pathogenesis of this disease. 
[56] 
There is evidence that psychological stress induces many 
ulcers and impairs response to treatment. This stress probably 
functions most often as a cofactor with H. pylori. It may act 
by stimulating the production of gastric acid or by promoting 
behavior that causes a risk to health. 
[57] Bleich et al in 1996 
and Sullivan et al in 1999 along with other researchers 
signify the relevance of emotional disturbance due to stress 
in the pathogenesis of peptic ulcer disease which cannot be 
ignored. 
[58-59] It has also been well reported that people who 
work the night shift have a frequently higher incidence of 
ulcers than day workers.
 [60]   
DIETARY ASPECTS 
Various types of food stimulate mucosal defense factors in 
experimental models. 
[61]  Incidence of peptic ulcer disease 
has decreased due to increase in the use of dietary essential 
fatty acids since the beginning of 20
th century.
 [62] Intake and 
handling of rice in various areas of the world may also 
explain peptic ulceration, as fresh rice oil in animal 
experiments protect against gastric ulceration, but stored oil 
is ulcerogenic. 
[63] Salt increases mortality from gastric but 
not duodenal ulcer. 
[64] Dietary fibre may be protective, as 
found in Swedish-Norwegian study, in which duodenal ulcers 
relapsed more quickly on a low fibre diet than on a bran Pahwa et al. / Clinical Manifestations, Causes and Management Strategies ………………. 
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supplemented diet. 
[65] Milk, on the other hand, seems to have 
an adverse effect on the healing rate of duodenal ulcers.
 [66] 
Duodenal ulceration is generally rare in areas of the world 
where the intake of dietary fibre in the form of unrefined 
wheat is the staple carbohydrate food eaten. 
[67] In 1978, 
Malhotra found that the rate of recurrence of duodenal 
ulceration was significantly lower in patients eating 
unrefined wheat compared to w h e n  t h e y  w e r e  o n  t h e i r  
previous more refined rice diet. 
[68]  Consequently, both 
animal studies as well as studies in human beings show that a 
diet rich in fibre protects the GIT against the development of 
peptic ulceration. 
SIGNS AND SYMPTOMS  
Moynihan, an Irish surgeon was the first to relate the clinical 
symptoms of peptic ulcer disease with the pathological 
findings. 
[69-70] It has been reported that small ulcers may not 
cause any symptoms and large ulcer can cause serious 
bleeding. 
[71] The most common symptom is burning pain, 
especially just below the breast bone. 
[72] Gastric ulcer pain 
may be less severe than duodenal ulcer pain and is noticeably 
higher in abdomen. Eating may increase pain in subjects 
rather than relieving pain. Other symptoms may include 
nausea, vomiting and weight loss. Vomiting might be related 
to partial or complete gastric outlet obstruction. Duodenal 
ulcer pain may awaken the patients from sleep and also 
involve burning or gnawing sensation in upper abdomen. 
Pain in back, lower abdomen or chest area may occasionally 
arise and occurs when the stomach is empty about two hours 
after a meal or during the night. Relief frequently occurs after 
eating. 
[73] Epigastric tenderness, melena resulting from acute 
or sub acute gastrointestinal bleeding and complete gastric 
outlet obstruction may also occur in ulcer disease. 
[74]  
 
DIAGNOSTIC TESTS 
Until early 20
th century, the diagnosis of peptic ulcer was 
made on clinical grounds. In 1950’s various flexible 
endoscopies revolutionized the direct visualization of ulcer 
disease. 
[75] Various diagnostic tests which are frequently 
employed by gastroenterologists depending upon patient’s 
symptoms are summarized in the following text. 
Esophagogastroduodenoscopy  
This is a special test performed by gastroenterologists in 
which a thin tube with a camera on the end is inserted 
through mouth into the GI tract to see stomach and small 
intestine. During this examination, the doctor may take a 
biopsy from the wall of stomach for detection of H. pylori. 
[71] 
X-ray 
In this, patient is made to swallow a white chalky substance 
called barium that is visible on X-ray and then patient is 
made to lie down on a tilted examining table. The tilting 
distributes the barium evenly around upper digestive tract 
and X-ray can capture images at different angles. This allows 
the doctor to locate the ulcer and determine its type and 
severity. 
[75] 
Computed tomography  
It is a rapid way to confirm an uncertain diagnosis of 
perforation and penetration associated with peptic ulcer 
disease. This study is carried out retrospectively to review the 
abdominal computed tomography findings in patients with 
peptic ulcer disease and correlated them with the clinical 
history, endoscopic and upper GIT series findings, and 
surgery when it is performed. 
[76-77] 
DIAGNOSIS OF H. PYLORI        
Diagnosis of H. pylori in peptic ulcer needs to be established 
before treatment is initiated. This can be done via 
noninvasive and/or invasive testing. The noninvasive tests 
include urea breath test, stool antigen test, and serology 
testing. 
[78]   
Urea breath test involves radioisotopes 
13C or 
14C, which help 
in identifying the production of urease by H. pylori. Patients 
ingest 
13C or 
14C labeled urea and then exhales labeled 
carbon dioxide. If H. pylori are present, since the bacterium 
produces urease this splits urea thereby, detecting the 
presence of the organism. False negative tests can occur if H. 
pylori is suppressed but not completely eliminated after 
treatment. 
[79] Several commercial stool antigen tests are also 
available. This test checks whether substances that trigger the 
immune system to fight an H. pylori infection are present in 
the feces of the patients infected with the bacterium. 
[80-81] 
Serology testing includes presence of human IgG antibodies 
against H. pylori. Antibody levels decline after treatment for 
infection and hence the positive antibody levels may indicate 
current or past infection. Antibodies for H. pylori can be 
measured in serum, plasma or whole blood. 
[82-83]  
Invasive testing includes endoscopy with subsequent 
histology, urease production testing and cultures allowing the 
clinician to identify the organism. Hematoxylin-eosin, 
Giemsa, or Warthin-Starry stains can be used in the detection 
and easier visualization of bacterium. Thus, many 
gastroenterologists utilizes urease test first, followed by 
histology, if the urease test is negative or if confirmation of 
the urease is desired. Culture is difficult to perform but it is 
helpful in evaluating treatment failure since antibiotic 
sensitivity can be evaluated. 
[84-85] The diagnostic tests for H. 
pylori are represented in table 1 along with their advantages. 
[86]
Table 1: Methods for diagnosis of H. pylori infection 
Test Advantages 
NON-INVASIVE   
Urea breath tests  High sensitivity and specificity 
Stool  antigen test  Cheap, accurate 
Serology  Rapid office kits available good for 
population studies 
INVASIVE (ANTRAL BIOPSY) 
Histology  Sensitivity and specificity 
Rapid urease tests  Cheap, quick specificity 
Microbiological culture  'Gold standard' defines antibiotic sensitivity 
 
COMPLICATIONS 
As the epidemiology of peptic ulcer has led to decreased 
incidence of this disease, it remains an important surgical 
problem because of the severity of its complications.  
Gastrointestinal bleeding  
Peptic ulcer disease is an important cause of upper-GI 
bleeding in 50 % of cases. 
[87] Upper GI bleeding is a 
common clinical problem, resulting in about 2,50,000 
hospitalizations in the U.S. annually. This disease is 
recognized the most common origin of upper-GI bleeding, 
accounting for 45 %-78 % of bleeding episodes. 
[88] The most 
frequent and severe complication of peptic ulcer is bleeding, 
which is reported 50 - 170 per 1, 00,000 with highest risk in 
people aged older than 60 years. 
[89] Bleeding is the deadliest 
complication of duodenal and gastric ulcer, accounting for 
almost all mortality in the surgical treatment of this disease. 
[90]  Patients whose ulcer reveals a flat dot or clean base 
(forrest class 3) rarely re-bleed or need hospitalization. 
However, actively bleeding ulcers or those with evidence of Pahwa et al. / Clinical Manifestations, Causes and Management Strategies ………………. 
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recent hemorrhage (forrest class 1 and 2) are likely to re-
bleed and may need intensive care. 
[91]  
Gastric outlet obstruction  
Other complication includes gastric outlet obstruction that is 
the obstruction at the pylorus from severe duodenal ulcer 
disease. This can occur because of extensive disease and 
subsequent scarring in the area, resulting in a mechanical 
blockage. Propulsive element of stomach, the antrum, 
becomes ineffective in efforts to evacuate the stomach 
because of the chronic impairment of normal emptying 
process from inflammation. 
[90] On the other hand, some 
authors have also concluded that gastric outlet obstruction is 
associated with high H. pylori infection rate. Taskin et al 
studied 10 consecutive patients presenting with clinically and 
endoscopically significant gastric outlet obstruction. During 
each endoscopy, seven gastric biopsy specimens were 
obtained (from the antrum, corpus and fundus) and analysed 
for  H. pylori colonization by both rapid urease test and 
histological methods. The antral mucosal biopsy specimens 
were H. pylori positive in nine patients, that is, in 90 % of 
patients. 
[92-93] 
Perforation  
Another complication is perforation of the gastric or 
duodenal ulcer. Survival is lower in ulcer perforation patients 
than in general population. 
[94] Perforation is less frequent 
than bleeding, with an incidence of around 7-10 per 1,00,000. 
[89]  
 
MANAGEMENT STRATEGIES 
Management of peptic ulcer disease continues to evolve 
because of the emergence of various novel therapeutic 
agents, advancements in several operative techniques and 
pharmacological oriented strategies. With the development of 
various therapies, as well as recognition and understanding of 
H. pylori infection  along with  mechanism, the medical 
management of ulcer has been largely successful. 
[95] Several 
drugs are extensively used for the reduction of acidity in 
peptic ulcer, gastroesophageal reflux disease and in many 
form of gastritis. Enormous drugs are also employed in the 
regimens for treating H. pylori infection. Various therapeutic 
agents utilized in management of ulcer and in the regimens 
for treating H. pylori infection includes H2 blockers, proton 
pump inhibitors, antacids, prostaglandins etc. 
[96] 
H2 receptor antagonists
 
Until the mid-1970s, there was no really effective medical 
treatment for duodenal ulcer. The outlook changed in 
November 1976, with the emergence of cimetidine, the first 
histamine H2 receptor antagonist which dramatically 
transformed management resulting in swift symptom relief, 
ulcer healing and marked reduction in relapse. 
[97] Various 
other H2 antagonists which are available in India; includes 
cimetidine, ranitidine, famotidine and roxatidine etc., others 
are also marketed in several countries. 
[98] These drugs are 
competitive inhibitors of histamine at the H2 receptor, thus 
suppressing gastrin stimulated acid secretion and 
proportionately reducing gastric juice volume. Histamine-
mediated pepsin secretion is also decreased. 
[96] Long-term 
continuous maintenance treatment with H2 receptor 
antagonists for five or more years effectively prevents ulcer 
recurrence in the majority of patients and significantly 
reduces the risk of ulcer complications. In addition, 
maintenance treatment has proved to be safe and is well 
tolerated by patients. 
[99]    
Proton pump inhibitors 
The first proton pump inhibitor (PPI) on the US market, 
omeprazole, appeared in 1988.This approval paved the way 
for the sequential introduction of other PPI congeners such as 
pantoprazole, lansoprazole rabeprazole, esomeprazole 
magnesium, the S-isomer of omeprazole etc. These are most 
potent suppressors of gastric acid secretion and inhibit gastric 
H
+K
+-ATPase enzyme (proton pump). 
[100] In typical doses, 
these drugs diminish the daily production of acid (basal and 
stimulated) by 80 % to 95 %. PPI are prodrugs that require 
activation in an acid environment. After absorption into the 
systemic circulation, the prodrug diffuses into parietal cells 
of the stomach and accumulates in the acidic secretory 
canaliculi. The activated form then binds covalently with 
sulfhydryl groups of cysteines in the H
+  K
+-ATPase, 
irreversibly inactivating the pump molecule. 
[101]  
Pantoprazole was first approved for use in the treatment of 
gastritis and duodenal ulcer in Germany in early 1994. 
[102] A 
single intravenous bolus of 80 mg of pantoprazole inhibits 
acid production by 80 % to 90 % within an hour, and this 
inhibition persists for up to 21 hours, permitting once-daily 
dosing to achieve the desired degree of hypochlorhydria. The 
FDA-approved dose of intravenous pantoprazole for 
gastroesophageal reflux disease is 40 mg daily for upto 10 
days. 
[101] The comparison of currently available proton pump 
inhibitors are described in table 2. 
[100] 
 
Table 2: Pharmacological comparison of currently available proton 
pump inhibitors 
PPI Bioavailability  Half-life  Renal/Hepatic  dosing 
Omeprazole 30-40% 0.1-1  h Reduce in hepatic 
impairment 
Esomeprazole 64%  1-1.5  h  Max. dose - 20 mg in 
severe hepatic impairment 
Pantoprazole 77% 3.5-10  h  None 
Lansoprazole >80%  2  h  Reduce in severe hepatic 
impairment 
Rabeprazole 52%  1-2  h  Use caution in severe 
hepatic impairment 
 
Antacids 
Antacids neutralize gastric acid and reduce pepsin activity. 
These agents relieve symptoms, promote ulcer healing, and 
decrease recurrence. They are relatively inexpensive. The 
optimal antacid regimen for ulcer healing generally includes 
10 to 30 ml of liquid or 2 to 4 tablets 1 h and 3 h after each 
meal and at bedtime. The total daily dosage of antacids 
should provide 200 - 400 mEq neutralizing capacity. 
However, antacids have been superseded by acid suppressive 
therapy in the treatment of peptic ulcer and are used only for 
short-term symptomatic relief. 
[96]
Anticholinergics 
Although anticholinergic medications inhibit basal and meal-
stimulated gastric acid secretion, they do so at a substantially 
lower rate than do other antisecretory agents. Also, 
significant adverse effects of nonselective anticholinergic 
agents limit their use in ulcer disease. 
[103]  
Misoprostol, Sucralfate, Carbenoxolone and Colloidal 
bisumth 
Naturally occurring prostaglandins have been shown to heal 
peptic ulcer in almost non-antisecretory doses. 
[104] However, 
these compounds are rapidly metabolized when given orally, 
and they also cause abdominal cramps, diarrhea, and uterine 
contractions. Therefore, in order to develop therapeutically 
effective prostaglandins, chemical and structural 
modifications are required. Significant number of Pahwa et al. / Clinical Manifestations, Causes and Management Strategies ………………. 
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prostaglandins analogues has been synthesized in search for a 
longer duration of action, increased potency, and greater 
pharmacological specificity. 
[105]
Prostaglandins especially misoprostol which is a synthetic 
prostaglandin E1 analogue protects against peptic ulcers by 
reducing gastric acid secretion, increasing bicarbonate 
production, and boost production of gastric mucus, a natural 
defense against peptic ulcers. Sucralfate is a sucrose-
aluminium complex that dissociates in the stomach, rapidly 
reacting with hydrochloric acid to form a thick, pasty 
substance that adheres to the gastric mucosa, especially to 
ulcer. By binding to the ulcer, sucralfate protects the ulcer 
from damaging effects of acid, pepsin and promoting healing. 
[106] Carbenoxolone is a derivative of glycyrrhizic acid, a 
constituent of liquorice. 
[107] It exerts  minimum inhibitory 
effect on gastric acid secretion.
 [108] It inhibits pepsin activity, 
stimulates mucus secretion and reduces gastric epithelial cell 
loss. 
[109] Tripotassium dicitrate bismuthate is colloidal 
bismuth. At low pH it binds to ulcerated mucosa and forms a 
protective layer lasting for about 6 h. It should therefore, be 
given before meals and at bedtime. 
[110]
Table 3: Some of recommended anti-Helicobacter regimens 
Triple antibiotics  Half life  Dose  Duration 
Bismuth subcitrate  -  120mg 4 times/day 
Tetracycline  9 h  500mg 4 times/day 
Metronidazole  8 h  400 mg 4 times/day 
1 week 
Two antibiotics with 
an antisecretory agent 
   
Amoxicillin  1 h  500 mg 3 times/day 
Metronidazole  8 h  400 mg 3 times/day 
Omeprazole 0.5-3  h  40  mg/day 
1 week 
      
Amoxicillin  1 h  1gm 2 times/day 
Clarithomycin  3-4 h  500 mg 2 times/day 
Omeprazole  0.5-3 h  20 mg 2 times/day 
1 week 
      
Amoxicillin  1 h  750 mg 3 times/day 
Metronidazole  8 h  500 mg 3 times/day 
Ranitidine  2-3 h  300 mg at bedtime 
 
2 weeks 
 
TREATMENT OF H. PYLORI 
H. pylori peptic ulcers are treated with various therapeutic 
agents that kill the bacteria, reduce stomach acid, and protect 
the stomach lining. Acid-suppressing drugs may also be used 
which includes H2 blockers, proton pump inhibitors etc. 
[111] 
The National Institute of Health Consensus Conference 
recommends combination of antimicrobial regimens for 
treatment of H. pylori. 
[112] In H. pylori related ulcers, 
combination of triple drug therapy have been necessary to 
eradicate this organism. 
[113] Original triple therapy, which 
combines bismuth subcitrate with metronidazole and 
tetracycline for a period of one to two weeks, is most widely 
used regimen for the treatment of H. pylori infection as 
depicted in Table 3. 
[114] Extensive efforts have been 
undertaken for the eradication of H. pylori with the 
administration of several drugs using dual or triple therapy. 
Various antimicrobial drugs employed to eradicate the 
bacterium, including amoxicillin, tetracycline, clarithromycin 
and metronidazole results in an effective treatment scheme in 
patients with H. pylori infection 
[115] Earlier it was a strong 
conviction according to Schwratz dictum that ‘No acid, No 
ulcer’ but in future, with the continuous efforts of scientific 
community worldwide, it will recognize that “No 
Helicobacter, No (or very few ulcer) ulcer”. 
[116]
Several studies have also documented a significant decrease 
in number and change in type of surgery starting in the mid 
1970s. Multiple factors have been implicated in our changing 
surgical management of patients. Introduction of novel 
pharmacotherapy has made significant impact on the 
frequency and presentation of peptic ulcer disease to 
surgeons. 
[117] This trend started, however already before the 
H2-antagonist era, thus perhaps rather reflecting changes in 
the incidence or severity of the disease. 
[118]  
FUTURE PERSPECTIVES 
Despite the remarkable achievements in various management 
strategies, few issues associated with this disease still remain 
unaddressed or partially defined. Exciting opportunities 
along with advanced pharmacotherapeutic approaches must 
be developed, and the mechanism involved in regulation of 
gastric acid secretion and H. pylori pathogenicity should be 
elucidated more evidently which holds great potential for the 
treatment in the future. Furthermore, innovative research 
should also attempt to solve the enigma related with various 
factors and causes on the prevalence of this disease. 
Extensive experiments must be carried out to establish the 
mechanisms and for development of new and safe drugs with 
advanced therapeutic interventions. Moreover, explorations 
in this field have to address the different etiologies of gastric 
and duodenal ulcer and other acid-peptic conditions as well 
as attempting to cure the disease rather than simply heal the 
ulcer. Advanced research on various novel gastroretentive 
dosage forms with several new antimicrobial agents for 
eradication of H. pylori infection would lead to management 
of complicated ulcer cases; thereby creating an exciting 
revolution in treatment strategies. Understanding and further 
study of complete genome of the bacterium should also aid in 
the development of most effective genetically engineered 
therapeutic regimens in times to come. Such knowledge 
might facilitate the design of specific vaccination regimens, 
allowing exclusive tissue-specific targeting drug delivery. 
New medical and pharmaceutical developments should also 
be conducted in close collaboration with gastroenterologist 
surgeons utilizing innovative surgical approaches.  
Peptic ulcers result from an imbalance between factors that 
maintain mucosal integrity with high concentration of acid 
and the proteolytic enzyme pepsin. Patients with peptic ulcer 
frequently have symptoms of indigestion and bowel 
dysfunction or acid related symptoms of pain and dyspepsia. 
H. pylori colonization of gastric mucosa is also recognized to 
be strongly associated with both chronic active gastritis and 
peptic ulcer disease. Enormous potential benefits of H. pylori 
eradication in the management of peptic ulcer disease will 
provide the necessary stimulus for continued research into 
the treatment of this infection. It is emphasized that suitable 
management and treatment strategies along with proper 
diagnosis of peptic ulcer are imperative considerations in 
decreasing patient morbidity and efficient eradication of the 
bacterium. 
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